RecruitingNCT07038239

Genotype/Phenotype Correlation of MORC2 Mutations

Deciphering MORC2 Genotype/Phenotype Correlation to Improve Patient Diagnostic


Sponsor

Hospices Civils de Lyon

Enrollment

45 participants

Start Date

Jun 16, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy. Different mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN. MORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.


Eligibility

Min Age: 4 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood sample and Skin biopsy for people with charcot-marie-tooth disease, difgan, and other related conditions. The study is currently recruiting participants at 12 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSkin biopsy

under the arm using a 3 mm punch, with local anaesthesia, in the investigating centres.

DIAGNOSTIC_TESTBlood sample

3 classical 4ml tubes samples per patients, using the routine blood sampling technique, in the investigating centres. For children, blood sampling volume will be adapted to the patient's weight according to L.1121-1 of the French public health code.


Locations(12)

CHU de Besançon

Besançon, France

CHRU Brest

Brest, France

CHU Grenoble

Grenoble, France

CH de Versailles

Le Chesnay, France

Service de Génétique moléculaire, pharmacogénétique, hormologie Hôpital Bicêtre

Le Kremlin-Bicêtre, France

Hospices Civils de Lyon

Lyon, France

CHU Marseille

Marseille, France

CHU de Nantes

Nantes, France

CH Pitié Salpêtrière

Paris, France

Hôpital Necker

Paris, France

CHU de Saint-Etienne

Saint-Etienne, France

CHU Strasbourg

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07038239


Related Trials